194 related articles for article (PubMed ID: 11764864)
1. Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections.
Manzella JP
Am Fam Physician; 2001 Dec; 64(11):1863-6. PubMed ID: 11764864
[TBL] [Abstract][Full Text] [Related]
2. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
[TBL] [Abstract][Full Text] [Related]
3. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
4. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.
Linden PK; Moellering RC; Wood CA; Rehm SJ; Flaherty J; Bompart F; Talbot GH;
Clin Infect Dis; 2001 Dec; 33(11):1816-23. PubMed ID: 11668430
[TBL] [Abstract][Full Text] [Related]
5. Quinupristin-dalfopristin and linezolid: evidence and opinion.
Eliopoulos GM
Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
7. Quinupristin/dalfopristin: a therapeutic review.
Allington DR; Rivey MP
Clin Ther; 2001 Jan; 23(1):24-44. PubMed ID: 11219478
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.
Summers M; Misenhimer GR; Antony SJ
South Med J; 2001 Mar; 94(3):353-5. PubMed ID: 11284529
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin-resistant Enterococcus faecium infections in the ICU and quinupristin/dalfopristin.
Zervos M
New Horiz; 1996 Aug; 4(3):385-92. PubMed ID: 8856757
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
11. Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin.
Fuller RE; Drew RH; Perfect JR
Pharmacotherapy; 1996; 16(4):584-92. PubMed ID: 8840364
[TBL] [Abstract][Full Text] [Related]
12. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
Lorian V; Fernandes F
Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
[TBL] [Abstract][Full Text] [Related]
13. Treatment of life-threatening multiresistant staphylococcal and enterococcal infections in patients with end-stage renal failure with quinupristin/dalfopristin: preliminary report.
Schwenger V; Mündlein E; Dagrosa EE; Fahr AM; Zeier M; Mikus G; Andrassy K
Infection; 2002 Oct; 30(5):257-61. PubMed ID: 12382082
[TBL] [Abstract][Full Text] [Related]
14. Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital.
Werner G; Klare I; Spencker FB; Witte W
J Antimicrob Chemother; 2003 Jul; 52(1):113-5. PubMed ID: 12805253
[TBL] [Abstract][Full Text] [Related]
15. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
Lundstrom TS; Sobel JD
Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
[TBL] [Abstract][Full Text] [Related]
16. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
[TBL] [Abstract][Full Text] [Related]
17. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
Klastersky J
Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
Pérez Salmerón J; Martínez García F; Roldán Conesa D; Lorente Salinas I; López Fornás F; Ruiz Gómez J; Gómez Gómez J; Segovia Hernández M; Valdés Chávarri M
Rev Esp Quimioter; 2006 Sep; 19(3):258-66. PubMed ID: 17099794
[TBL] [Abstract][Full Text] [Related]
19. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.
Moellering RC; Linden PK; Reinhardt J; Blumberg EA; Bompart F; Talbot GH
J Antimicrob Chemother; 1999 Aug; 44(2):251-61. PubMed ID: 10473233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
